Oxedrine
CAS 94-07-5
Oxedrine (CAS 94-07-5) is a pharmaceutical compound with 2 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 16705.39090909091 nM | 30 | - |
| - | AC50 | 7327.3 nM | 3 | - |
| - | IC50 | 19976.309999999998 nM | 1 | - |
| - | EC50 | 6600 nM | 1 | - |
| - | Ki | 63000 nM | 1 | - |
| 5-hydroxytryptamine receptor 1A GPCR |
Ki | 4.2 | - | Homo sapiens |
| Neuromedin-U receptor 2 GPCR |
EC50 | 5.18 | - | Homo sapiens |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Oxedrine used for in pharmaceutical contexts?
Oxedrine (CAS 94-07-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Oxedrine?
No adverse-event association or SIDER side-effect rows are rendered for Oxedrine in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Oxedrine also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Synephrine with EU status "restricted".
What clinical phase is Oxedrine in?
No phase 1-4 clinical development badge is rendered for Oxedrine because the matched compound identifier rows do not contain a max-phase value.
What bioactivity targets are documented for Oxedrine?
Oxedrine has 7 bioactivity rows in this page query. Rendered target entries include 5-hydroxytryptamine receptor 1A, Neuromedin-U receptor 2.